Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers

Hiroshi Kotani, Yuta Adachi, Hidenori Kitai, Shuta Tomida, Hideaki Bando, Anthony C. Faber, Takayuki Yoshino, Dominic C. Voon, Seiji Yano, Hiromichi Ebi

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

BRAF is one of the most frequently mutated genes across a number of different cancers, with the best-characterized mutation being V600E. Despite the successes of treating BRAF mutant V600E lung cancer with BRAF pathway inhibitors, treatment strategies targeting tumors with non-V600E mutations are yet to be established. We studied cellular signaling differences between lung cancers with different BRAF mutations and determined their sensitivities to BRAF pathway inhibitors. Here, we observed that MEK inhibition induced feedback activation of the receptor tyrosine kinase (RTK) EGFR, and in some cases the RTK FGFR, resulting in transient suppression of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells. Furthermore, we found that both EGFR and FGFR activated the MEK/ERK pathway, despite the presence of BRAF non-V600E mutations with elevated kinase activity. Moreover, in BRAF non-V600E mutants with impaired kinase activities, EGFR had even greater control over the MEK/ERK pathway, essentially contributing completely to the tonic mitogen-activated protein kinase (MAPK) signal. Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. Furthermore, the results were recapitulated with a clinically relevant dual inhibitor of EGFR and RAF, BGB-283. Overall, although BRAF V600E mutant cells are sensitive to BRAF inhibition, non-V600E mutant cancer cells are reliant on RTKs for their MAPK activation and inhibiting both MEK and RTKs are necessary in these cancers. Our findings provide evidence of critical survival signals in BRAF non-V600E mutant cancers, which could pave the way for effective treatment of these cancers.

Original languageEnglish
Pages (from-to)1775-1787
Number of pages13
JournalOncogene
Volume37
Issue number13
DOIs
Publication statusPublished - Mar 1 2018

Fingerprint

Receptor Protein-Tyrosine Kinases
Mitogen-Activated Protein Kinases
Lung Neoplasms
Mitogen-Activated Protein Kinase Kinases
Neoplasms
Mutation
MAP Kinase Signaling System
Phosphotransferases
Phosphorylation
Genes

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. / Kotani, Hiroshi; Adachi, Yuta; Kitai, Hidenori; Tomida, Shuta; Bando, Hideaki; Faber, Anthony C.; Yoshino, Takayuki; Voon, Dominic C.; Yano, Seiji; Ebi, Hiromichi.

In: Oncogene, Vol. 37, No. 13, 01.03.2018, p. 1775-1787.

Research output: Contribution to journalArticle

Kotani, H, Adachi, Y, Kitai, H, Tomida, S, Bando, H, Faber, AC, Yoshino, T, Voon, DC, Yano, S & Ebi, H 2018, 'Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers', Oncogene, vol. 37, no. 13, pp. 1775-1787. https://doi.org/10.1038/s41388-017-0035-9
Kotani, Hiroshi ; Adachi, Yuta ; Kitai, Hidenori ; Tomida, Shuta ; Bando, Hideaki ; Faber, Anthony C. ; Yoshino, Takayuki ; Voon, Dominic C. ; Yano, Seiji ; Ebi, Hiromichi. / Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers. In: Oncogene. 2018 ; Vol. 37, No. 13. pp. 1775-1787.
@article{bf26e1aa181f4796989e1e8c5598cc2b,
title = "Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers",
abstract = "BRAF is one of the most frequently mutated genes across a number of different cancers, with the best-characterized mutation being V600E. Despite the successes of treating BRAF mutant V600E lung cancer with BRAF pathway inhibitors, treatment strategies targeting tumors with non-V600E mutations are yet to be established. We studied cellular signaling differences between lung cancers with different BRAF mutations and determined their sensitivities to BRAF pathway inhibitors. Here, we observed that MEK inhibition induced feedback activation of the receptor tyrosine kinase (RTK) EGFR, and in some cases the RTK FGFR, resulting in transient suppression of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells. Furthermore, we found that both EGFR and FGFR activated the MEK/ERK pathway, despite the presence of BRAF non-V600E mutations with elevated kinase activity. Moreover, in BRAF non-V600E mutants with impaired kinase activities, EGFR had even greater control over the MEK/ERK pathway, essentially contributing completely to the tonic mitogen-activated protein kinase (MAPK) signal. Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. Furthermore, the results were recapitulated with a clinically relevant dual inhibitor of EGFR and RAF, BGB-283. Overall, although BRAF V600E mutant cells are sensitive to BRAF inhibition, non-V600E mutant cancer cells are reliant on RTKs for their MAPK activation and inhibiting both MEK and RTKs are necessary in these cancers. Our findings provide evidence of critical survival signals in BRAF non-V600E mutant cancers, which could pave the way for effective treatment of these cancers.",
author = "Hiroshi Kotani and Yuta Adachi and Hidenori Kitai and Shuta Tomida and Hideaki Bando and Faber, {Anthony C.} and Takayuki Yoshino and Voon, {Dominic C.} and Seiji Yano and Hiromichi Ebi",
year = "2018",
month = "3",
day = "1",
doi = "10.1038/s41388-017-0035-9",
language = "English",
volume = "37",
pages = "1775--1787",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "13",

}

TY - JOUR

T1 - Distinct dependencies on receptor tyrosine kinases in the regulation of MAPK signaling between BRAF V600E and non-V600E mutant lung cancers

AU - Kotani, Hiroshi

AU - Adachi, Yuta

AU - Kitai, Hidenori

AU - Tomida, Shuta

AU - Bando, Hideaki

AU - Faber, Anthony C.

AU - Yoshino, Takayuki

AU - Voon, Dominic C.

AU - Yano, Seiji

AU - Ebi, Hiromichi

PY - 2018/3/1

Y1 - 2018/3/1

N2 - BRAF is one of the most frequently mutated genes across a number of different cancers, with the best-characterized mutation being V600E. Despite the successes of treating BRAF mutant V600E lung cancer with BRAF pathway inhibitors, treatment strategies targeting tumors with non-V600E mutations are yet to be established. We studied cellular signaling differences between lung cancers with different BRAF mutations and determined their sensitivities to BRAF pathway inhibitors. Here, we observed that MEK inhibition induced feedback activation of the receptor tyrosine kinase (RTK) EGFR, and in some cases the RTK FGFR, resulting in transient suppression of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells. Furthermore, we found that both EGFR and FGFR activated the MEK/ERK pathway, despite the presence of BRAF non-V600E mutations with elevated kinase activity. Moreover, in BRAF non-V600E mutants with impaired kinase activities, EGFR had even greater control over the MEK/ERK pathway, essentially contributing completely to the tonic mitogen-activated protein kinase (MAPK) signal. Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. Furthermore, the results were recapitulated with a clinically relevant dual inhibitor of EGFR and RAF, BGB-283. Overall, although BRAF V600E mutant cells are sensitive to BRAF inhibition, non-V600E mutant cancer cells are reliant on RTKs for their MAPK activation and inhibiting both MEK and RTKs are necessary in these cancers. Our findings provide evidence of critical survival signals in BRAF non-V600E mutant cancers, which could pave the way for effective treatment of these cancers.

AB - BRAF is one of the most frequently mutated genes across a number of different cancers, with the best-characterized mutation being V600E. Despite the successes of treating BRAF mutant V600E lung cancer with BRAF pathway inhibitors, treatment strategies targeting tumors with non-V600E mutations are yet to be established. We studied cellular signaling differences between lung cancers with different BRAF mutations and determined their sensitivities to BRAF pathway inhibitors. Here, we observed that MEK inhibition induced feedback activation of the receptor tyrosine kinase (RTK) EGFR, and in some cases the RTK FGFR, resulting in transient suppression of ERK phosphorylation in BRAF non-V600E, but not BRAF V600E, mutant cells. Furthermore, we found that both EGFR and FGFR activated the MEK/ERK pathway, despite the presence of BRAF non-V600E mutations with elevated kinase activity. Moreover, in BRAF non-V600E mutants with impaired kinase activities, EGFR had even greater control over the MEK/ERK pathway, essentially contributing completely to the tonic mitogen-activated protein kinase (MAPK) signal. Accordingly, the combination of MEK inhibitor with EGFR inhibitor was effective at shrinking tumors in mouse model of BRAF non-V600E mutant lung cancer. Furthermore, the results were recapitulated with a clinically relevant dual inhibitor of EGFR and RAF, BGB-283. Overall, although BRAF V600E mutant cells are sensitive to BRAF inhibition, non-V600E mutant cancer cells are reliant on RTKs for their MAPK activation and inhibiting both MEK and RTKs are necessary in these cancers. Our findings provide evidence of critical survival signals in BRAF non-V600E mutant cancers, which could pave the way for effective treatment of these cancers.

UR - http://www.scopus.com/inward/record.url?scp=85040668150&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85040668150&partnerID=8YFLogxK

U2 - 10.1038/s41388-017-0035-9

DO - 10.1038/s41388-017-0035-9

M3 - Article

C2 - 29348459

AN - SCOPUS:85040668150

VL - 37

SP - 1775

EP - 1787

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 13

ER -